Evidence map›Paper›PMID 25505934›Full record

ArticleGenome medicine2014

YMAP: a pipeline for visualization of copy number variation and loss of heterozygosity in eukaryotic pathogens.

Darren A Abbey, Jason Funt, Mor N Lurie-Weinberger, Dawn A Thompson, Aviv Regev, Chad L Myers, Judith Berman

Abstract read
In one paragraph

Article in Genome medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed.

  1. Article
  2. Paralogs of thebioRxiv : the preprint server for biology · 2026
    Article
  3. Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. ER stress selects forFrontiers in microbiology · 2026
    Article
  8. Article
  9. The rise ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Induction of pan-azole resistance inFrontiers in cellular and infection microbiology · 2025
    Article
  18. Dual adaptive strategies inFrontiers in microbiology · 2025
    Article
  19. Caspofungin paradoxical growth inFrontiers in cellular and infection microbiology · 2025
    Article
  20. Aneuploidy enables adaptation to brefeldin A inFrontiers in cellular and infection microbiology · 2025
    Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Darren A AbbeyDepartment of Genetics, Cell Biology and Development, University of Minnesota, 6-160 Jackson Hall, Minneapolis, MN 55415 USA.
Jason FuntBroad Institute of MIT and Harvard University, 415 Main Street, Cambridge, MA 02142 USA.
Mor N Lurie-WeinbergerDepartment of Molecular Microbiology and Biotechnology, Tel Aviv University, 418 Britannia Building, Ramat Aviv, 69978 Israel.
Dawn A ThompsonBroad Institute of MIT and Harvard University, 415 Main Street, Cambridge, MA 02142 USA.
Aviv RegevBroad Institute of MIT and Harvard University, 415 Main Street, Cambridge, MA 02142 USA.
Chad L MyersDepartment of Computer Science and Engineering, University of Minnesota, 200 Union St SE, Minneapolis, MN 55455 USA.
Judith BermanDepartment of Genetics, Cell Biology and Development, University of Minnesota, 6-160 Jackson Hall, Minneapolis, MN 55415 USA ; Department of Molecular Microbiology and Biotechnology, Tel Aviv University, 418 Britannia Building, Ramat Aviv, 69978 Israel.

Funding

PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8M
Genome-wide analysis of regulated chromosomal domains: From mechanisms to cancerR01CA119176 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI REGEV, AVIV, SEGAL, ERAN · 2006 to 2015
$3.7M
NCI NIH HHS R01 CA119176NIGMS NIH HHS T32 GM007287
6 · The paper itself

Abstract

The design of effective antimicrobial therapies for serious eukaryotic pathogens requires a clear understanding of their highly variable genomes. To facilitate analysis of copy number variations, single nucleotide polymorphisms and loss of heterozygosity events in these pathogens, we developed a pipeline for analyzing diverse genome-scale datasets from microarray, deep sequencing, and restriction site associated DNA sequence experiments for clinical and laboratory strains of Candida albicans, the most prevalent human fungal pathogen. The YMAP pipeline (http://lovelace.cs.umn.edu/Ymap/) automatically illustrates genome-wide information in a single intuitive figure and is readily modified for the analysis of other pathogens with small genomes.

Identifiers

PMID25505934
PMCPMC4263066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.